Teva Pharmaceutical Industries Ltd. Makes Statement on DEFINE Study Results

Mörfelden-Walldorf, (PresseBox) - We acknowledge the results of the DEFINE study seem promising for patients. It is important to note that as a general rule, results obtained in clinical trials in multiple sclerosis (MS) cannot be compared, unless agents are tested in a head-to-head manner in the same trial.

Methodological differences between the DEFINE and ALLEGRO studies, mainly in the definition of the key endpoints, only underscore the inability to compare these two important clinical trials.

There are many considerations when choosing a treatment for MS. Based on the ALLEGRO results, Teva believes that laquinimod has the potential to be a safe, convenient and effective, once-daily oral therapy option with a unique mechanism of action that will address unmet needs for MS patients.

It is important to remember that MS affects each person differently. It is of vital importance that patients have numerous treatment options available to choose from in order to find a therapy that best meets their needs and manages their symptoms. We are proud to offer patients COPAXONE® today, and look forward to bringing our laquinimod product to market in the future.

Teva's goal is to make quality healthcare accessible to patients around the world.

Teva Deutschland GmbH

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for relapsing-remitting multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.